Simcere Pharmaceutical Group Limited reported unaudited revenue of RMB4.58 billion for the six months ended 30 June 2026, up 27.8% year-on-year. Innovative pharmaceuticals contributed 84.9% of total turnover, climbing 34.1% to RMB3.89 billion.

Profit attributable to equity shareholders reached RMB0.83 billion, a 37.9% increase. Adjusted profit, which excludes fair-value movements and financing-related items, grew 48.7% to RMB0.96 billion.

Segment-wise, Neuroscience remained the largest contributor at RMB2.01 billion (+60.9%), representing 43.9% of total revenue. Autoimmune sales rose 37.8% to RMB1.21 billion, while Anti-oncology advanced 5.8% to RMB0.93 billion. Revenue from other therapeutic areas declined 25.2% to RMB0.44 billion.

R&D expenditure totalled RMB0.88 billion, equivalent to 19.2% of revenue, as the pipeline expanded to 11 first-patient-in studies and five last-patient-in completions during the period. Three new IND approvals were secured for pan-RAS inhibitor SIM0532, LRRC15 ADC SIM0613 and PD-1/VEGF bispecific SIM0689.

The commercial portfolio was strengthened by continued uptake of Sanbexin, QUVIVIQ and COSELA, and inclusion of Sanbexin injection in China’s National Essential Medicines List. Licensing activity remained active, highlighted by global out-licensing deals for SIM0709 with Boehringer Ingelheim and SIM0660 with Roche, pushing cumulative overseas licensing value above USD6.1 billion.

Operational cash flow rose to RMB1.61 billion (1H25: RMB0.86 billion). Cash, equivalents and time deposits stood at RMB5.20 billion, against RMB1.06 billion of bank borrowings, leaving the current ratio at 190.2% and the gearing ratio at 38.6%.

The board did not declare an interim dividend. Simcere reiterated its focus on bolstering global R&D capabilities, advancing clinical programs and leveraging artificial intelligence to support drug discovery and commercialization.